The emergence of PARP inhibitors brought new hope, but only 10-20% of patients with ovarian cancer carry BRCA1/2 mutations, and the need for a first-line maintenance treatment has not been met [21]. This evidence concerns the gene BRCA1 and ovarian carcinoma.